Skip to content

EB Pharma Developments

Active
Private limited companyfounded 2022active for 4 yearsAlkerstraat 28, 3570 Alken, BelgiumKBO/BCE: BE 0780.755.671
Summary

EB Pharma Developments has been active since 2022 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €5,298 and a net result of -€1,347. Equity is shrinking by about 27% per year and would, assuming unchanged policy, indicatively turn negative around financial year 2027. Its solvency ranks better than 40% of 791 sector peers (NACE 74, financial year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).

Overview

Activity
Other professional, scientific and technical activities
NACE 74999
1 site
Size
€16,951total assets 2025
Equity
€5,298
Loss
-€1,347
Turnover not published (abbreviated or micro format)
Financial health
90 Excellent Checked score 2025
Bankruptcy probabilitywithin 12 months
0.1%
Structure
Accounts 128 days early0 of 1 deed read
Why 90lowers riskSector: Other professional, scientific and technical activities (NACE 74)Liquidity: current ratio 1.45, cash €8,736Figures for financial year 2025 (filed 26-03-2026)Size: total assets €16,951Show the evidence

Checked score

Score 2025
90 / 100
Excellent
Probability in this band: under 0.55%
Financially better than 30% of its sector peers (NACE 74, micro)
Financial strength · tick = 2024
Average
Solvency 56-44
equity 31.3% of total assets
Liquidity 63-35
short-term debt 68.7% · cash 51.5%
Profitability 18-66
return on assets -7.9%
Bankruptcy probability, 12 months
0.1% Very low
0%0.5%1.5%4%10%≥ 25%

About 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.2% (5,409 companies, NACE 74, micro)
Last 24 months 11-2024: 0.1% 12-2024: 0.1%● unchanged vs 11-2024 01-2025: 0.1%● unchanged vs 12-2024 02-2025: 0.1%● unchanged vs 01-2025 03-2025: 0.1%● unchanged vs 02-2025 04-2025: 0.1%● unchanged vs 03-2025 05-2025: 0.2%▲ +0.1 percentage points vs 04-2025 06-2025: 0.2%● unchanged vs 05-2025 07-2025: 0.2%● unchanged vs 06-2025highest value 08-2025: 0.1%▼ -0.1 percentage points vs 07-2025 09-2025: 0.1%● unchanged vs 08-2025 10-2025: 0.1%● unchanged vs 09-2025 11-2025: 0.1%● unchanged vs 10-2025 12-2025: 0.1%● unchanged vs 11-2025 01-2026: 0.1%● unchanged vs 12-2025lowest value 02-2026: 0.1%● unchanged vs 01-2026 03-2026: 0.1%● unchanged vs 02-2026 04-2026: 0.1%● unchanged vs 03-2026 05-2026: 0.1%● unchanged vs 04-2026 06-2026: 0.1%● unchanged vs 05-2026 07-2026: 0.1%● unchanged vs 06-2026 08-2026: 0.1%● unchanged vs 07-2026 09-2026: 0.1%● unchanged vs 08-2026 10-2026: 0.1%● unchanged vs 09-2026
How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 74, micro): better than 36% on solvency, 54% on liquidity, 20% on profitability and 10% on growth.

The bankruptcy probability was computed on 10-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Five signals.
lowers riskneutral
lowers risk · Sector: Other professional, scientific and technical activities (NACE 74)
KBO
lowers risk · Liquidity: current ratio 1.45, cash €8,736
NBB · annual accounts
lowers risk · Figures for financial year 2025 (filed 26-03-2026)
NBB · annual accounts
lowers risk · Size: total assets €16,951
The company's size counts in the probability; how much depends on the rest of its profile.
NBB · annual accounts
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 25-03-2026, 128 days ahead of the deadline.
NBB · 4 filings
Deviation from the deadline
2025
128 days early
2024
6 days early
2023
1 day early
2022
22 days late
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 4 accounts on average 28 days before the deadline; the sector median (NACE 74) for financial year 2024 is 3 days before the deadline, and 38% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 28 July (3 of the last 4 filed years within 30 days of that day).
Companies Code · seven months
Where today falls in the filing period
11-10-2026 today31-12-2026 year end31-07-2027 deadline
neutral · No strike-offs in the KBO publications
Searched since incorporation in 2022.
KBO publications · our coverage
  1. Annual accounts filedfinancial year 2025 · abbreviated…
  2. Annual accounts filedfinancial year 2024 · abbreviated…
  3. Back to profitnet €3,567

Financials · financial year 2025, abbreviated format

Equity
€5,298▼ 68.2%
2024 · €16,645
Total assets
€16,951▼ 11.1%
2024 · €19,064
Net result
-€1,347
2024 · €3,567
Working capital
€5,298▼ 68.2%
2024 · €16,645
Trend over the years

2022 to 2025, 4 financial years

The operating result turns negative in 2025: a loss of €1,589 after €3,300 in 2024.

What the company sold each financial year and what was left of it. A loss stands below the zero line.

Operating result-€1,589 2025 Net result-€1,347 2025

Use the arrow keys on the chart for the figures per year.

Sector: the middle half of NACE 74, Other professional, scientific and technical activities: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30. Dashed line: the median. Available for Net result, Equity, Total assets, Working capital, Solvency, Current ratio, Return on assets (ROA).

Every figure with its change against the financial year before
favourable unfavourable
Line2022202320242025
Operating result€20,616--€4,744€3,300-€1,589
Net result€16,222within the sector's middle half--€4,644below the sector's middle half€3,567within the sector's middle half-€1,347within the sector's middle half
Equity€17,722within the sector's middle half-€13,078below the sector's middle half▼ 26.2%€16,645below the sector's middle half▲ 27.3%€5,298below the sector's middle half▼ 68.2%
Total assets€22,037below the sector's middle half-€13,078below the sector's middle half▼ 40.7%€19,064below the sector's middle half▲ 45.8%€16,951below the sector's middle half▼ 11.1%
Debt€4,316-€0▼ 100%€2,420€11,654▲ 382%
Working capital€17,722within the sector's middle half-€13,078within the sector's middle half▼ 26.2%€16,645within the sector's middle half▲ 27.3%€5,298within the sector's middle half▼ 68.2%
Solvency80.4%above the sector's middle half-100.0%above the sector's middle half▲ 19.6pp87.3%above the sector's middle half▼ 12.7pp31.3%within the sector's middle half▼ 56.1pp
Current ratio5.11above the sector's middle half-7.88above the sector's middle half1.45within the sector's middle half▼ 6.42
Return on assets (ROA)73.6%above the sector's middle half--35.5%below the sector's middle half▼ 109.1pp18.7%above the sector's middle half▲ 54.2pp-7.9%below the sector's middle half▼ 26.7pp
above within below the middle half of NACE 74, Other professional, scientific and technical activities: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30.
Turnover and EBIT margin not published: the abbreviated or micro format does not require them.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Equity and liabilities €16,951
Equity €5,298 ▼ 68.2%
Debt €11,654 ▲ 382%
Debt's share of the balance-sheet total rises from 12.7% to 68.7%. Equity is lower and debt is higher.
Key figures and ratios
2025 value · change against 2024
Debt to equity
2.20▲
2024 · 0.15
ROE
-25.4%▼
2024 · 21.4%
Debt ≤ 1 year
€11,654▲
2024 · €2,420
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.

Peer companies

Historical observation

Of the 2,146 companies that looked in July 2024 the way this one looks now, 2.2% went bankrupt within 24 months and 92% are still going.

  • Micro
  • 2 to 5 years old
  • solvency 30% or more
  • a small loss
2.2% went bankrupt
5.9% stopped otherwise
92% still going

A further 0.1% stopped, but we cannot tell whether within those 24 months.

For this company itself Checked computes a lower bankruptcy probability: 0.1% over twelve months. The score reads more about this company than the group's four characteristics; both figures are right about what they measure.

How reliable is this rule?

Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,470 companies of July 2024 its group's bankruptcy share. Expected: 1.6%; actually bankrupt within 24 months: 1.7%.

The companies in ten equal groups, from lowest to highest expected share.
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 1.0%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 3.0% 3.1%
10 5.6% 6.2%

The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.

An observation about 2,146 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.

Annual accounts
Filed annual accounts As filed with the NBB · 2025 against 2024 · 33 lines
Balance sheet Code20242025
Assets
Total assets20/58€19,064€16,951▼
Current assets29/58€19,064€16,951▼
Amounts receivable within one year40/41€9,445€8,215▼
Trade receivables40€3,880€0▼
Other amounts receivable41€5,565€8,215▲
Cash at bank and in hand54/58€9,619€8,736▼
Equity and liabilities
Total equity and liabilities10/49€19,064€16,951▼
Equity10/15€16,645€5,298▼
Contributions10/11€1,500€1,500=
Reserves13€15,145€3,798▼
Distributable reserves133€15,145€3,798▼
Profit (loss) carried forward14-€0
Amounts payable17/49€2,420€11,654▲
Amounts payable within one year42/48€2,420€11,654▲
Trade debts44€1,920€636▼
Suppliers440/4€1,920€636▼
Other amounts payable47/48€500€11,018▲
Income statement Code20242025
Other operating charges640/8€449€462▲
Gross operating margin9900€3,749-€1,127▼
Operating profit (loss)9901€3,300-€1,589▼
Financial income75/76B€1,675€364▼
Recurring financial income75€1,675€364▼
Financial charges65/66B€1,408€123▼
Recurring financial charges65€1,408€123▼
Profit (loss) for the period before taxes9903€3,567-€1,347▼
Profit (loss) for the period9904€3,567-€1,347▼
Profit (loss) for the period to be appropriated9905€3,567-€1,347▼
Appropriation of the result
Profit (loss) to be appropriated9906€3,567-€1,347▼
Transfer from equity791/2€0€11,347▲
Transfer to equity691/2€3,567€0▼
To other reserves6921€3,567€0▼
Profit to be distributed694/7-€10,000
Return on contributions (dividend)694-€10,000

The notes to these accounts (2 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Line2022202320242025Change
Other operating charges640/8€348€446€449€462▲ 2.8%
Gross operating margin9900€20,964-€4,297€3,749-€1,127▼ 130%
Operating profit (loss)9901€20,616-€4,744€3,300-€1,589▼ 148%
Financial income75/76B-€196€1,675€364▼ 78.2%
Recurring financial income75-€196€1,675€364▼ 78.2%
Financial charges65/66B€79€97€1,408€123▼ 91.3%
Recurring financial charges65€79€97€1,408€123▼ 91.3%
Profit (loss) for the period before taxes9903€20,537-€4,644€3,567-€1,347▼ 138%
Income taxes67/77€4,316€0---
Profit (loss) for the period9904€16,222-€4,644€3,567-€1,347▼ 138%
Profit (loss) for the period to be appropriated9905€16,222-€4,644€3,567-€1,347▼ 138%
Line2022202320242025Change
Assets
Total assets20/58€22,037€13,078€19,064€16,951▼ 11.1%
Current assets29/58€22,037€13,078€19,064€16,951▼ 11.1%
Amounts receivable within one year40/41€9,555€8,378€9,445€8,215▼ 13.0%
Trade receivables40-€823€3,880€0▼ 100%
Other amounts receivable41€9,555€7,555€5,565€8,215▲ 47.6%
Cash at bank and in hand54/58€12,482€4,700€9,619€8,736▼ 9.2%
Equity and liabilities
Total equity and liabilities10/49€22,037€13,078€19,064€16,951▼ 11.1%
Equity10/15€17,722€13,078€16,645€5,298▼ 68.2%
Contributions10/11€1,500€1,500€1,500€1,500=
Reserves13€16,222€11,578€15,145€3,798▼ 74.9%
Distributable reserves133€16,222€11,578€15,145€3,798▼ 74.9%
Profit (loss) carried forward14---€0-
Amounts payable17/49€4,316€0€2,420€11,654▲ 382%
Amounts payable within one year42/48€4,316€0€2,420€11,654▲ 382%
Trade debts44--€1,920€636▼ 66.9%
Suppliers440/4--€1,920€636▼ 66.9%
Taxes, remuneration and social security45€4,316€0---
Taxes450/3€4,316€0---
Other amounts payable47/48--€500€11,018▲ 2,104%
Line2022202320242025Change
Profit (loss) for the period9904€16,222-€4,644€3,567-€1,347▼ 138%
Operating cash flow (approximation)€16,222-€4,644€3,567-€1,347▼ 138%
Change in cash--€7,782€4,919-€883▼ 118%

Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.

Download as CSV

Public contracts: not fully processed yet. The notices from August 2023 to September 2026 are still being read.

Directors

Directors
No directors read yet: 0 of 1 Gazette act processed. See the directors and other office holders in the KBO →

Owners and capital

Owners

No owners or capital events in the accounts and acts we read.

History

On 21 January 2022, EB Pharma Developments was incorporated as a private limited company.1 Total assets went from €22,037 in 2022 to €16,951 in 2025.2

  1. 1KBO (Crossroads Bank for Enterprises)
  2. 2National Bank, annual accounts 2022 and 2025

Acts, filings and financial milestones

Next filing, financial year 2026, expected by 31-07-2027
2026
25-03
NBB filing Annual accounts filed
financial year 2025 · abbreviated format
2025
25-07
NBB filing Annual accounts filed
financial year 2024 · abbreviated format
2024
31-12
Financial Back to profitnet €3,567
Net result €3,567 after one loss-making year.
30-07
NBB filing Annual accounts filed
financial year 2023 · abbreviated format
2023
31-12
Financial Weakest financial yearnet -€4,644
Net result drops to -€4,644, the lowest in the series; recovery starts the following year.
22-08
NBB filing Annual accounts filed
financial year 2022 · micro format · 22 days late
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
0 of 1 deed read
About the unread acts

We know of 1 Belgian Official Gazette act for this company. It has not been read yet: what they contain is neither established nor disproved here.

Have them read with priority Sign in to place this company at the front of the reading queue.

Register details

Identification
Legal formPrivate limited company
Founded21-01-2022
Financial year end31-12
Activities, NACEBEL 2025
74999Other professional, scientific and technical activities
72101Research and development on biotechnology
72109Other research and development on natural sciences
E-invoicing
Reachable via Peppol
Peppol ID 0208:0780755671
Also 9925:BE0780755671
Registered 23-04-2026

If you follow this company, Checked tells you the day it leaves the Peppol register.

Register as of 11 October 2026 · Peppol Directory

Scores and ratios are computed by Checked and are not a credit decision.

Environmental permits: No permit applications found in Flanders. Brussels and Wallonia do not publish the applicant.

Sites & property

Location & real-estate footprint
Registered office, Alken · 1 establishment unit since 2022
registered office establishment The establishment unit on the map
Ground area
1,294 m²
Building footprint
443 m²
Building volume
2,153 m³
Parcel 73302E1060/00A002, Flanders · tallest building 9.7 m. Linked by address, not a title deed.
4 companies at this address See who is registered here
1 establishment unit
EB Pharma Developments
Alkerstraat 28, 3570 AlkenResearch and development on biotechnology
since 2022unit no. 2.327.009.214
1 parcel
Flanders 1 (100%)
Cadastral parcel Region Area Buildings Height / floors
73302E1060/00A002 Flanders 1,293 m² 1 · 443 m² 9.7 m · 1
How the parcels are linked
Good to know
The parcel matches the address exactly.